ICU Management & Practice, ICU Volume 9 - Issue 1 - Spring 2009

Combined Technology
Offers Excellence in Patient Monitoring Solutions

Covidien, a leading global supplier of healthcare products, with its Nellcor™ OxiMax™ oximetry system is now integrated into Dräger bedside monitors with the new Infinity® SmartPod® with Nellcor™ OxiMax™ oximetry system.


Physicians now have access to the flexibility to choose the OxiMax™ system with Dräger patient monitors. Dräger's new Infinity SmartPod with Nellcor OxiMax pulse oximetry system, which is primarily installed in critical care areas such as the Emergency, OR and NICU departments, incorporates the latest Nellcor OxiMax low-power pulse oximetry system. This allows the Infinity monitors* to be compatible with Covidien's family of innovative specialty sensors, which only work with Nellcor OxiMax technology, including the Max- Fast™ forehead sensor used for patients with poor perfusion and the SoftCare™ nonadhesive sensor line for patients with sensitive skin.


Chris Lowery, General Manager/Vice President, Patient Monitoring division of Covidien, stated, "The integration of our OxiMax system into Dräger monitors offers greater value to customers by providing access to the best in class technology of both organisations. We are especially excited to extend the reach of our specialty sensors which are in such high demand and will now be available to support an even greater number of clinicians for improved patient outcomes."


The Nellcor pod incorporates cardiac-based signal processing algorithms, enabling clinicians to track SpO2 and pulse rate, even during difficult monitoring challenges such as during signal interference or low perfusion. "The new Nellcor pod expands Dräger's portfolio of SpO2 solutions and gives our customers the opportunity to take advantage of the Nellcor OxiMax oximetry system," says Heidi Trott, Senior Product Manager for Dräger. "This technology expands the value of Dräger's patented Pick and Go® solution, which enables all vital sign parameters that were being monitored at the bedside to continue to be monitored on transport, even during challenging patient transports between units."

«« Facebook to Ask Users to Share Organ Donor Status


EMA Release Septrin Adverse Reaction Reports »»